Press Release Épalinges, Switzerland, June 15th, 2026 Cross-industry white paper calls for three paradigm shifts to unlock orphan drug
Paradigm shifts and strategic recommendations from Volv Global, Sanofi, Fondation Ipsen, Unitechpharma, and brave2change Orphan drug development faces barriers: approximately
Pompe disease is a rare, chronically debilitating metabolic disorder caused by deficiency of the enzyme acid alpha-glucosidase. As enzyme replacement
Press Release Épalinges, Switzerland, June 1st, 2026 Machine Learning Maps and Discovers Clinical Endpoints in Pompe Disease Using Real-World
Tech Tour Growth Health is one of Europe’s most established gatherings at the intersection of healthcare innovation and investment –
Volv Global is pleased to be participating in the Life Sciences Innovation & Investment Corridor between Lausanne & London, hosted
Volv Global researches how machine learning on de-identified real-world data can characterise diseases that are rarely coded, to help pharma
The ISPOR International Annual Conference 2026 brings together global leaders in health economics and outcomes research to explore the
Inflammatory Bowel Disease (IBD) management has evolved significantly with advanced therapies and data-driven care strategies. Yet, one persistent issue continues
Introduction Advocacy plays a critical role in accelerating progress in rare diseases. As technology advances, collaboration between patient communities, researchers,
As our commemoration of Rare Disease Day 2026, we are pleased to present a guest article by Jessica Lynn at
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction Earlier cancer detection remains one of the most powerful opportunities
